Healthcare entrepreneurs Richard Anderson and Spencer Kerry have launched Impel Healthcare Catalysts, an investment company designed to be a catalyst for innovation and growth in the healthcare sector. 

Headquartered in Knutsford, Impel will provide growth capital along with strategic expertise, primarily to businesses based in the UK, making use of the management team’s broad healthcare knowledge and track record to deliver rapid growth and strong returns. It will typically invest in companies with enterprise values up to £50m initially, and also has the capability to co-invest with other debt and equity funders. 

MIME Technologies, a med-tech spin-out from the University of Aberdeen, has raised a combined £255,000 from first round investment and a Scottish Enterprise grant.

Designed to revolutionise the support given to cabin crew during in-flight medical events, MIME Technologies’ innovative product can monitor a passenger’s vital signs while communicating with clinicians on the ground.

Mogrify Ltd, a UK company aiming to transform the development of life-saving cell therapies, has announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date. The funding will support internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest. Mogrify is also actively recruiting, and will increase headcount to 60 scientific, operational and commercial staff located at its state-of-the-art facility on Cambridge Science Park.

Inflexion Private Equity has agreed to acquire Pharmaspectra, a leading global provider of medical affairs data to the pharmaceutical and biotech industry. The investment is being made by Inflexion Enterprise Fund IV, Inflexion’s dedicated lower mid?market fund.

Founded in 2005, Pharmaspectra is the leader in providing scientific dissemination data and analytics to the pharmaceutical industry. Pharmaspectra’s data is utilised by 7 of the world’s top 10 pharmaceutical companies. The firm has offices in the UK, US, Switzerland, and India.

London-based Lifted has raised £1.5m in seed funding to transform the home care sector. The startup has been founded by Zero 1, a new corporate venture builder which is working with FTSE 100 corporate partners, to build companies that can tackle the world’s biggest challenges. 

Echopoint Medical Ltd, a spinout company from UCL, has raised £2.8m to develop optical sensing technology to help heart disease patients in a grey zone where the need for treatment is unclear.

Coronary heart disease is a major cause of death worldwide and more than 7 million* people have a diagnosis in the UK alone. Narrowing arteries caused by the disease are commonly treated by the insertion of tiny tubes called stents, but the process is both risky and expensive.

Ortho Solutions, a specialist orthopaedic design manufacturer, has secured a £2 million funding facility from Independent Growth Finance (IGF) to develop a new range of innovative medical solutions. Founded in 2001, the privately-owned Essex based manufacturer supplies NHS and private hospitals throughout the UK with implant systems used in foot and ankle surgery.

Kare Plus National Limited has received a £910,000 loan from MEIF Maven WM Debt Finance, part of the Midlands Engine Investment Fund.

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, has announced the completion of its latest funding round. The over-subscribed fund-raise was supported by new and existing investors, led by Archangel Investors and including Scottish Investment Bank (the investment arm of Scottish Enterprise, Scotland’s national economic development agency), Barwell and TriCapital Investors.

Blackfinch Ventures has invested £540,000 into innovate start-up Kokoon. The London based company has developed the world’s first sleep aiding headphones, allowing customers to take control of their sleep. Kokoon has developed noise cancelling headphones that include bio-sensors, measuring when the wearer falls asleep.  The product is specifically designed to help the customer sleep using its relaxing audio and soundscapes. The connected app, Kokoon Relax, monitors and tracks the users’ sleep journey, providing suggested audio that is specifically designed to protect the user from disturbances throughout the night.

Clyde Biosciences Ltd. has raised a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd.

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome Tim Rea, an investor at BGF, to its board.